A physician’s guide to the 2-dose schedule of MenB-FHbp vaccine

References

• Cohn AC, MacNeil JR, Clark TA, Ortega-Sanchez IR, Briere EZ, Meissner HC, Baker CJ, Messonnier NE, Centers for Disease Control and Prevention. Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2013;62(RR–2):1–28. pii: rr6202a1.
   PubMed Web of Science ®Google Scholar
• Folaranmi T, Rubin L, Martin SW, Patel M, MacNeil JR. Use of serogroup B meningococcal vaccines in persons aged ≥10 years at increased risk for serogroup B meningococcal disease: recommendations of the Advisory Committee on Immunization Practices, 2015. MMWR Morb Mortal Wkly Rep. 2015;64:608–12.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Enhanced meningococcal disease surveillance report, 2016 [accessed 2018 Sept 26]. https://www.cdc.gov/meningococcal/downloads/NCIRD-EMS-Report.pdf.
   Google Scholar
• Mbaeyi SA, Joseph SJ, Blain A, Wang X, Hariri S, MacNeil JR. Meningococcal disease among college-aged young adults: 2014-2016. Pediatrics. 2019;143(1):e20182130. doi:10.1542/peds.2018-2130.
   PubMed Web of Science ®Google Scholar
• Trumenba® (meningococcal group B vaccine). Full prescribing information. Philadelphia (PA): Wyeth Pharmaceuticals Inc., a subsidiary of Pfizer Inc; 2017.
   Google Scholar
• Pace D, Pollard AJ. Meningococcal disease: clinical presentation and sequelae. Vaccine. 2012;30(suppl 2):B3–B9. doi:10.1016/j.vaccine.2011.12.062.
   PubMed Web of Science ®Google Scholar
• Martinón-Torres F. Deciphering the burden of meningococcal disease: conventional and under-recognized elements. J Adolesc Health. 2016;59(2 suppl):S12–20. doi:10.1016/j.jadohealth.2016.03.041.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Meningococcal meningitis. [accessed 2018 Sept 26]. http://www.who.int/immunization/diseases/meningitis/en/.
   Google Scholar
• Harrison LH, Trotter CL, Ramsay ME. Global epidemiology of meningococcal disease. Vaccine. 2009;27(suppl 2):B51–63. doi:10.1016/j.vaccine.2009.04.063.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Enhanced meningococcal disease surveillance report, 2017 [accessed 2018 Nov 30]. https://www.cdc.gov/meningococcal/downloads/NCIRD-EMS-Report-2017.pdf.
   Google Scholar
• Centers for Disease Control and Prevention. Enhanced meningococcal disease surveillance report, 2015 [accessed 2018 June 19]. https://www.cdc.gov/meningococcal/downloads/NCIRD-EMS-Report-2015.pdf.
   Google Scholar
• Christensen H, May M, Bowen L, Hickman M, Trotter CL. Meningococcal carriage by age: a systematic review and meta-analysis. Lancet Infect Dis. 2010;10(12):853–61. doi:10.1016/S1473-3099(10)70251-6.
   PubMed Web of Science ®Google Scholar
• Meyer S. Epidemiology of meningococcal disease among college students – United States, 2014-2016 [accessed 2018 Apr 2]. https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2018-02/Mening-02-Meyer-508.pdf.
   Google Scholar
• Biswas HH, Han GS, Wendorf K, Winter K, Zipprich J, Perti T, Martinez L, Arellano A, Kyle JL, Zhang P, et al. Notes from the field: outbreak of serogroup B meningococcal disease at a university - California, 2016. MMWR Morb Mortal Wkly Rep. 2016;65(20):520–21. doi:10.15585/mmwr.mm6520a3.
   PubMed Web of Science ®Google Scholar
• Meyer S. Update on the epidemiology of meningococcal disease and guidance for the control of meningococcal disease outbreaks in the U.S. [accessed 2018 Sept 26]. https://pdfs.semanticscholar.org/presentation/e0b3/aa069eb91e1d831b8c40d4340d21afa4c513.pdf.
   Google Scholar
• De Maria A. Update: invasive meningococcal cases at the University of Massachusetts (UMass) Amherst. Jamaica Plain (MA): Commonwealth of Massachusetts Department of Public Health, editor; 2017.
   Google Scholar
• California Health Alert Network San Diego. Invasive meningococcal disease outbreak at San Diego State University; County of San Diego: San Diego, CA 2018.
   Google Scholar
• Menactra® (meningococcal [groups A, C, Y and W-135] polysaccharide diphtheria toxoid conjugate vaccine). Full prescribing information. Swiftwater (PA): Sanofi Pasteur Inc.; 2016.
   Google Scholar
• Menveo® (meningococcal [groups A, C, Y and W-135] oligosaccharide diphtheria CRM197 conjugate vaccine). Full prescribing information. Sovicille (Italy): GSK Vaccines S.r.l.; 2017.
   Google Scholar
• NIMENRIX (meningococcal polysaccharide serogroups A, C, W-135 and Y conjugate vaccine). Summary of product characteristics. Sandwich (Kent, UK): Pfizer Limited; 2017.
   Google Scholar
• Bexsero (MenB-4C). Summary of product characteristics. Siena (Italy): GlaxoSmithKline Vaccines Srl.; 2018.
   Google Scholar
• MacNeil JR, Rubin LG, Patton M, Ortega-Sanchez IR, Martin SW. Recommendations for use of meningococcal conjugate vaccines in HIV-infected persons — Advisory Committee on Immunization Practices, 2016. MMWR Morb Mortal Wkly Rep. 2016;65(43):1189–94. doi:10.15585/mmwr.mm6543a3.
   PubMed Web of Science ®Google Scholar
• Patton ME, Stephens D, Moore K, MacNeil JR. Updated recommendations for use of MenB-FHbp serogroup B meningococcal vaccine — advisory Committee on Immunization Practices, 2016. MMWR Morb Mortal Wkly Rep. 2017;66(19):509–13. doi:10.15585/mmwr.mm6619a6.
   PubMed Web of Science ®Google Scholar
• McNeil LK, Zagursky R, Shuo L, Murphy E, Zlotnick G, Hoiseth SK, Jansen KU, Andersen AS. The role of factor H binding protein in Neisseria meningitidis virulence and its potential as a vaccine candidate to broadly protect against meningococcal disease. Microbiol Mol Biol Rev. 2013;77(2):234–52. doi:10.1128/MMBR.00056-12.
   PubMed Web of Science ®Google Scholar
• MacNeil JR, Rubin L, Folaranmi T, Ortega-Sanchez IR, Patel M, Martin SW. Use of serogroup B meningococcal vaccines in adolescents and young adults: recommendations of the Advisory Committee on Immunization Practices, 2015. MMWR Morb Mortal Wkly Rep. 2015;64(41):1171–76. doi:10.15585/mmwr.mm6441a3.
   PubMed Web of Science ®Google Scholar
• Donald RG, Hawkins JC, Hao L, Liberator P, Jones TR, Harris SL, Perez JL, Eiden JJ, Jansen KU, Anderson AS. Meningococcal serogroup B vaccines: estimating breadth of coverage. Hum Vaccin Immunother. 2017;13(2):255–65. doi:10.1080/21645515.2017.1264750.
   PubMed Web of Science ®Google Scholar
• Goldschneider I, Gotschlich EC, Artenstein MS. Human immunity to the meningococcus. I. The role of humoral antibodies. J Exp Med. 1969;129:1307–26.
   PubMed Web of Science ®Google Scholar
• Borrow R, Aaberge IS, Santos GF, Eudey TL, Oster P, Glennie A, Findlow J, Hoiby EA, Rosenqvist E, Balmer P, et al. Interlaboratory standardization of the measurement of serum bactericidal activity by using human complement against meningococcal serogroup b, strain 44/76-SL, before and after vaccination with the Norwegian MenBvac outer membrane vesicle vaccine. Clin Diagn Lab Immunol. 2005;12(8):970–76. doi:10.1128/CDLI.12.8.970-976.2005.
   PubMedGoogle Scholar
• Andrews N, Borrow R, Miller E. Validation of serological correlate of protection for meningococcal C conjugate vaccine by using efficacy estimates from postlicensure surveillance in England. Clin Diagn Lab Immunol. 2003;10(5):780–86. doi:10.1128/CDLI.10.5.780-786.2003.
   PubMedGoogle Scholar
• Borrow R, Carlone GM, Rosenstein N, Blake M, Feavers I, Martin D, Zollinger W, Robbins J, Aaberge I, Granoff DM, et al. Neisseria meningitidis group B correlates of protection and assay standardization–international meeting report Emory University, Atlanta, Georgia, United States, 16-17 March 2005. Vaccine. 2006;24:5093–107.
   PubMed Web of Science ®Google Scholar
• Granoff DM, Pollard AJ, Harrison LH. Meningococcal capsular group B vaccines. In: Plotkin SA, Orenstein WA, Offit PA, Edwards KM editors. Plotkin’s Vaccines. Elsevier: Philadelphia, PA; 2018. p. 644–662.e646.
   Google Scholar
• Ostergaard L, Vesikari T, Absalon J, Beeslaar J, Ward BJ, Senders S, Eiden JJ, Jansen KU, Anderson AS, York LJ, et al. A bivalent meningococcal B vaccine in adolescents and young adults. N Engl J Med. 2017;377(24):2349–62. doi:10.1056/NEJMoa1614474.
   PubMed Web of Science ®Google Scholar
• McNeil LK, Donald RGK, Gribenko A, French R, Lambert N, Harris SL, Jones TR, Li S, Zlotnick G, Vogel U, et al. Predicting the susceptibility of meningococcal serogroup B isolates to bactericidal antibodies elicited by bivalent rLP2086, a novel prophylactic vaccine. MBio. 2018;9(2):e00036–00018. doi:10.1128/mBio.00036-18.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Assessment report: Trumenba [accessed 2017 July 7]. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/004051/WC500228997.pdf.
   Google Scholar
• Perez JL, Absalon J, Beeslaar J, Balmer P, Jansen KU, Jones TR, Harris S, York LJ, Jiang Q, Radley D, et al. From research to licensure and beyond: clinical development of MenB-FHbp, a broadly protective meningococcal B vaccine. Expert Rev Vaccines. 2018;17(6):461–77. doi:10.1080/14760584.2018.1483726.
   PubMed Web of Science ®Google Scholar
• Vesikari T, Wysocki J, Beeslaar J, Eiden J, Jiang Q, Jansen KU, Jones TR, Harris SL, O’Neill RE, York LJ, et al. Immunogenicity, safety, and tolerability of bivalent rLP2086 meningococcal group B vaccine administered concomitantly with diphtheria, tetanus, and acellular pertussis and inactivated poliomyelitis vaccines to healthy adolescents. J Pediatric Infect Dis Soc. 2016;5(2):180–87. doi:10.1093/jpids/piv064.
   PubMed Web of Science ®Google Scholar
• Muse D, Christensen S, Bhuyan P, Absalon J, Eiden JJ, Jones TR, York LJ, Jansen KU, O’Neill RE, Harris SL, et al. A phase 2, randomized, active-controlled, observer-blinded study to assess the immunogenicity, tolerability and safety of bivalent rLP2086, a meningococcal serogroup B vaccine, coadministered with tetanus, diphtheria and acellular pertussis vaccine and serogroup A, C, Y and W-135 meningococcal conjugate vaccine in healthy US adolescents. Pediatr Infect Dis J. 2016;35(6):673–82. doi:10.1097/INF.0000000000001124.
   PubMed Web of Science ®Google Scholar
• Senders S, Bhuyan P, Jiang Q, Absalon J, Eiden J, Jones TR, York LJ, Jansen KU, O’Neill RE, Harris SL, et al. Immunogenicity, tolerability, and safety in adolescents of bivalent rLP2086, a meningococcal serogroup B vaccine, coadministered with quadrivalent human papilloma virus vaccine. Pediatr Infect Dis J. 2016;35(5):548–54. doi:10.1097/INF.0000000000001072.
   PubMed Web of Science ®Google Scholar
• Vesikari T, Ostergaard L, Diez-Domingo J, Wysocki J, Flodmark CE, Beeslaar J, Eiden J, Jiang Q, Jansen KU, Jones TR, et al. Meningococcal serogroup B bivalent rLP2086 vaccine elicits broad and robust serum bactericidal responses in healthy adolescents. J Pediatric Infect Dis Soc. 2016;5(2):152–60. doi:10.1093/jpids/piv039.
   PubMed Web of Science ®Google Scholar
• Study B1971012 Data on File. New York (NY): Pfizer Inc; 2013.
   Google Scholar
• Gu XX, Plotkin SA, Edwards KM, Sette A, Mills KHG, Levy O, Sant AJ, Mo A, Alexander W, Lu KT, et al. Waning immunity and microbial vaccines — workshop of the National Institute of Allergy and Infectious Diseases. Clin Vaccine Immunol. 2017;24:7. doi:10.1128/cvi.00034-17.
   Web of Science ®Google Scholar
• Vesikari T, Ostergaard L, Beeeslaar J, Absalon J, Eiden JJ, Jansen KU, Jones TR, Harris SL, Maansson R, Munson S, et al. Persistence and 4-year boosting of the bactericidal response elicited by two- and three-dose schedules of MenB-FHbp: A phase 3 extension study in adolescents. Vaccine. 2019;37:1710–9. doi:10.1016/j.vaccine.
   Web of Science ®Google Scholar
• Reiner DM, Bhuyan P, Eiden JJ, Ginis J, Harris S, Jansen KU, Jiang Q, Jones TR, O’Neill RE, York LJ, et al. Immunogenicity, safety, and tolerability of the meningococcal serogroup B bivalent rLP2086 vaccine in adult laboratory workers. Vaccine. 2016;34(6):809–13. doi:10.1016/j.vaccine.2015.12.016.
   PubMed Web of Science ®Google Scholar
• Harris SL, Donald RG, Hawkins JC, Tan C, O’Neill R, McNeil LK, Perez JL, Anderson AS, Jansen KU, Jones TR. Neisseria meningitidis serogroup B vaccine, bivalent rLP2086, induces broad serum bactericidal activity against diverse invasive disease strains including outbreak strains. Pediatr Infect Dis J. 2017;36(2):216–23. doi:10.1097/INF.0000000000001399.
   PubMed Web of Science ®Google Scholar
• Taha MK, Hawkins JC, Liberator P, Deghmane AE, Andrew L, Hao L, Jones TR, McNeil LK, O’Neill RE, Perez JL, et al. Bactericidal activity of sera from adolescents vaccinated with bivalent rLP2086 against meningococcal serogroup B outbreak strains from France. Vaccine. 2017;35(11):1530–37. doi:10.1016/j.vaccine.2017.01.066.
   PubMed Web of Science ®Google Scholar
• Lujan E, Partidge E, Giuntini S, Ram S, Granoff DM. Breadth and duration of meningococcal serum bactericidal activity in health care workers and microbiologists immunized with the MenB-FHbp vaccine. Clin Vaccine Immunol. 2017;24:e00121–00117. doi:10.1128/CVI.00121-17.
   PubMed Web of Science ®Google Scholar
• Wang X, Cohn A, Comanducci M, Andrew L, Zhao X, MacNeil JR, Schmink S, Muzzi A, Bambini S, Rappuoli R, et al. Prevalence and genetic diversity of candidate vaccine antigens among invasive Neisseria meningitidis isolates in the United States. Vaccine. 2011;29(29–30):4739–44. doi:10.1016/j.vaccine.2011.04.092.
   PubMed Web of Science ®Google Scholar
• Rajam G, Stella M, Kim E, Paulos S, Boccadifuoco G, Serino L, Carlone G, Medini D. Meningococcal antigen typing system (MATS)-based Neisseria meningitidis serogroup B coverage prediction for the MenB-4C vaccine in the United States. mSphere. 2017;2(6). doi:10.1128/mSphere.00261-17.
   PubMed Web of Science ®Google Scholar
• Bexsero (meningococcal group B vaccine). Full prescribing information. Sovicille (SI) (Italy): GSK Vaccines, Srl; 2018.
   Google Scholar
• Perrett KP, McVernon J, Richmond PC, Marshall H, Nissen M, August A, Percell S, Toneatto D, Nolan T. Immune responses to a recombinant, four-component, meningococcal serogroup B vaccine (4CMenB) in adolescents: a phase III, randomized, multicentre, lot-to-lot consistency study. Vaccine. 2015;33(39):5217–24. doi:10.1016/j.vaccine.2015.06.103.
   PubMed Web of Science ®Google Scholar
• Block SL, Szenborn L, Daly W, Jackowska T, D’Agostino D, Han L, Dull PM, Smolenov I. A comparative evaluation of two investigational meningococcal ABCWY vaccine formulations: results of a phase 2 randomized, controlled trial. Vaccine. 2015;33(21):2500–10. doi:10.1016/j.vaccine.2015.03.001.
   PubMed Web of Science ®Google Scholar
• Santolaya ME, O’Ryan ML, Valenzuela MT, Prado V, Vergara R, Munoz A, Toneatto D, Grana G, Wang H, Clemens R, et al. Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b/3 randomised, observer-blind, placebo-controlled study. Lancet. 2012;379(9816):617–24. doi:10.1016/S0140-6736(11)61713-3.
   PubMed Web of Science ®Google Scholar
• Banzhoff A. Multicomponent meningococcal B vaccination (4CMenB) of adolescents and college students in the United States. Ther Adv Vaccines. 2017;5(1):3–14. doi:10.1177/2051013616681365.
   PubMedGoogle Scholar
• Basta NE, Mahmoud AA, Wolfson J, Ploss A, Heller BL, Hanna S, Johnsen P, Izzo R, Grenfell BT, Findlow J, et al. Immunogenicity of a meningococcal B vaccine during a university outbreak. N Engl J Med. 2016;375(3):220–28. doi:10.1056/NEJMoa1514866.
   PubMed Web of Science ®Google Scholar
• Basta N, Wolfson J, Mahmoud A, Heller B, Ploss A, Halloran ME, Bai X, Findlow H, Borrow B. 4CMenB vaccine immunogenicity up to 1 year after vaccination among university students. Paper presented at: International Pathogenic Neisseria Conference; 2018; Asilomar, CA, USA.
   Google Scholar
• Parikh SR, Andrews NJ, Beebeejaun K, Campbell H, Ribeiro S, Ward C, White JM, Borrow R, Ramsay ME, Ladhani SN. Effectiveness and impact of a reduced infant schedule of 4CMenB vaccine against group B meningococcal disease in England: a national observational cohort study. Lancet. 2016;388(10061):2775–82. doi:10.1016/S0140-6736(16)31921-3.
   PubMed Web of Science ®Google Scholar
• Rand CM, Goldstein NPN. Patterns of primary care physician visits for US adolescents in 2014: implications for vaccination. Acad Pediatr. 2018;18(2s):S72–S78. doi:10.1016/j.acap.2018.01.002.
   PubMedGoogle Scholar
• C.S. Mott Children’s Hospital, National Poll on Children’s Health. Parents not keeping up with teen vaccines [accessed 2018 September 26]. http://mottpoll.org/reports-surveys/parents-not-keeping-teen-vaccines.
   Google Scholar
• Kempe A, Allison MA, MacNeil JR, O’Leary ST, Crane LA, Beaty BL, Hurley LP, Brtnikova M, Lindley MC, Liang JL, et al. Knowledge and attitudes regarding category B ACIP recommendations among primary care providers for children. Acad Pediatr. 2018;18(7):763–68. doi:10.1016/j.acap.2018.04.005.
   PubMed Web of Science ®Google Scholar
• Marshall GS, Tan L. Understanding the category B recommendation for serogroup B meningococcal vaccine. Pediatrics. 2017;139(5):e20163484. doi:10.1542/peds.2016-3484.
   PubMed Web of Science ®Google Scholar
• Kempe A, Allison MA, MacNeil JR, O’Leary ST, Crane LA, Beaty BL, Hurley LP, Brtnikova M, Lindley MC, Albert AP. Adoption of serogroup B meningococcal vaccine recommendations. Pediatrics. 2018;142(3):e20180344. doi:10.1542/peds.2018-0344.
   PubMed Web of Science ®Google Scholar
• Brady MT. Strength and clarity of vaccine recommendations influence providers’ practice. Pediatrics. 2018;142(3):e20181633. doi:10.1542/peds.2018-1633.
   PubMed Web of Science ®Google Scholar
• Huang L, Goren A, Lee L, Dempsey A, Srivastava A. Disparities in Healthcare Providers’ Interpretation and Implementation of ACIP’s Meningococcal Vaccine Recommendations. Paper presented at: IDWeek; 2018; San Francisco, CA.
   Google Scholar
• Walker TY, Elam-Evans LD, Yankey D, Markowitz LE, Williams CL, Mbaeyi SA, Fredua B, Stokley S. National, regional, state, and selected local area vaccination coverage among adolescents aged 13-17 years - United States, 2017. MMWR Morb Mortal Wkly Rep. 2018;67(33):909–17. doi:10.15585/mmwr.mm6733a1.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Recommended immunization schedule for children and adolescents aged 18 years or younger, United States, 2018 [accessed 2018 Sept 26]. https://www.cdc.gov/vaccines/schedules/hcp/imz/child-adolescent.html.
   Google Scholar
• Adolescent Immunization Initiative. Rationale for an immunization platform at 16 years of age [accessed 2018 June 14]. https://www.give2mcv4.org/content/uploads/2017/03/rationale-for-16-year-old-immunization-platform.pdf.
   Google Scholar
• Atkinson W, Immunization Action Coalition. Adolescent immunization update and the 16-year-old platform [accessed 2018 Sept 26]. www.immunize.org/catg.d/S8005.pdf.
   Google Scholar
• Society for Adolescent Health and Medicine. Establishing an immunization platform for 16-year-olds in the United States. J Adolesc Health. 2017;60(4):475–76. doi:10.1016/j.jadohealth.2017.01.011.
   PubMedGoogle Scholar
• Centers for Disease Control and Prevention. Recommended immunization schedule for children and adolescents aged 18 years or younger, United States, 2017 [accessed 2018 Jan 9]. https://www.cdc.gov/vaccines/schedules/hcp/imz/child-adolescent.html.
   Google Scholar